Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects

被引：0
作者：
Chanan Shaul
Simcha Blotnick
Mordechai Muszkat
Meir Bialer
Yoseph Caraco
机构：
[1] Hadassah-Hebrew University Medical Center,Clinical Pharmacology Unit, Division of Medicine
[2] Hebrew University,Institute of Drug Research, School of Pharmacy, Faculty of Medicine
来源：
Molecular Diagnosis & Therapy | 2017年 / 21卷
关键词：
Warfarin; Variant Allele; Warfarin Dose; Oral Clearance; CYP2C9 Genotype;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：75 / 83
页数：8
相关论文
共 50 条
[41]   Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study [J].
Sridharan, Kannan ;
Modi, Tanvi ;
Bendkhale, Shital ;
Kulkarni, Devranth ;
Gogtay, Nithya J. ;
Thatte, Urmila M. .
CURRENT CLINICAL PHARMACOLOGY, 2016, 11 (01) :62-68
[42]   CYP2C9 polymorphisms: Considerations in NSAID therapy [J].
Ali, Zaynah K. ;
Kim, Rebekah J. ;
Ysla, Francis M. .
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (01) :108-114
[43]   Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement [J].
Quinn, Alison L. H. ;
Liko, Ina ;
Lee, James C. .
PHARMACOGENOMICS, 2017, 18 (11) :1051-1057
[44]   Frequencies of CYP2C9 polymorphisms in a Syrian cohort [J].
Aldiban, Weam ;
Aljamali, Majd N. ;
Youssef, Lama A. .
BMC GENOMICS, 2025, 26 (01)
[45]   Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients [J].
Natarajan, Sripriya ;
Ponde, Chandrashekhar K. ;
Rajani, Rajesh M. ;
Jijina, Farah ;
Gursahani, Roopkumar ;
Dhairyawan, Pradnya P. ;
Ashavaid, Tester F. .
PHARMACOLOGICAL REPORTS, 2013, 65 (05) :1375-1382
[46]   Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients [J].
Sripriya Natarajan ;
Chandrashekhar K. Ponde ;
Rajesh M. Rajani ;
Farah Jijina ;
Roopkumar Gursahani ;
Pradnya P. Dhairyawan ;
Tester F. Ashavaid .
Pharmacological Reports, 2013, 65 :1375-1382
[47]   The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients' Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm [J].
Khaleqsefat, Esmat ;
Khalaj-Kondori, Mohammad ;
Bonyadi, Mortaza Jabarpour ;
Soraya, Hamid ;
Askari, Behnam .
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (03) :77-85
[48]   Frequency of CYP2C9 and VKORC1 Gene Polymorphisms and Their Influence on Warfarin Dose in Egyptian Pediatric Patients [J].
Mennat-Allah Kamal El-Din ;
Marwa Salah Farhan ;
Randa Ibrahim El Shiha ;
Rania Mohammed Helmy El-Kaffas ;
Somaia Mohammed Mousa .
Pediatric Drugs, 2014, 16 :337-341
[49]   Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects [J].
Li, Z. ;
Wang, G. ;
Wang, L. -S. ;
Zhang, W. ;
Tan, Z. -R. ;
Fan, L. ;
Chen, B. -L. ;
Li, Q. ;
Liu, J. ;
Tu, J. -H. ;
Hu, D. -L. ;
Liu, Z. -Q. ;
Zhou, H. -H. .
XENOBIOTICA, 2009, 39 (10) :788-793
[50]   Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients [J].
Taisei Mushiroda ;
Yozo Ohnishi ;
Susumu Saito ;
Atsushi Takahashi ;
Yuka Kikuchi ;
Shigeru Saito ;
Hideki Shimomura ;
Yasuhiko Wanibuchi ;
Takao Suzuki ;
Naoyuki Kamatani ;
Yusuke Nakamura .
Journal of Human Genetics, 2006, 51 :249-253
12345